Background: Early accurate detection of acute kidney injury (AKI) occurring after cardiac surgery may improve morbidity and mortality. Although several novel biomarkers have been developed for the early detection of AKI, their clinical utility in the critical intraoperative and immediate postoperative period remains unclear.
short-term mortality. 3 Even mild AKI, defined as a 25% increase in serum creatinine level over baseline, is associated with a doubling in long-term mortality up to 10 years after surgery. 4 The negative effect of AKI is independent of other prognostic factors and persists even if kidney function recovers to baseline. 4 Furthermore, AKI increases the risk for subsequent chronic kidney disease and kidney failure, with its associated morbidity and mortality. 5 Cardiac surgery-associated AKI results from the interplay between patient susceptibility to kidney injury and intraoperative kidney insults. The dominant mechanism of injury is thought to be intraoperative ischemia-reperfusion injury. Data from animal studies show that AKI due to ischemia-reperfusion injury is potentially reversible, [6] [7] [8] [9] [10] provided that the therapeutic intervention is administered at or shortly after the time of injury, during a window of time corresponding to the initiation or early extension phases of ischemiareperfusion injury. 11, 12 Currently, the diagnosis of AKI relies on serum creatinine level, which takes 2 to 3 days to increase above a defined threshold due to the rate-limiting step of creatinine production and release by skeletal muscle. Interventions administered at the time of AKI diagnosis using elevated serum creatinine level may not be effective, as has been demonstrated in multiple clinical trials of promising therapies for AKI in humans. [13] [14] [15] Accordingly, a biomarker that can detect AKI early may facilitate intervention within this narrow window of reversibility. Ideally, such a biomarker would identify injury as it occurs intraoperatively or at least within a few hours after surgery. Recent research efforts have identified multiple proteins that may provide the basis for early diagnosis of AKI. [16] [17] [18] [19] We hypothesized that some of these novel biomarkers could predict postoperative AKI accurately. We therefore conducted a systematic review and meta-analysis of the diagnostic performance of early urinary, plasma, and serum biomarkers of cardiac surgery-associated AKI.
METHODS

Design, Search Strategy, and Study Selection
We performed a systematic review of the literature to assess the association of novel urine, serum, and plasma biomarkers with the early identification of AKI following adult cardiac surgery. The search strategy was designed and implemented under the guidance of a medical librarian (K.M.). The following electronic databases were searched from January 1, 1990, to January 1, 2015: EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Library, Scopus, and PubMed. The search strategy was tailored to each database and included a combination of key words and subject headings. Key words used included AKI, acute kidney injury, kidney failure, kidney disease, cardiac surgery, prognosis, diagnosis, biomarkers, NGAL, neutrophil gelatinase associated lipocalin, IL-18, interleukin 18, KIM1, kidney injury molecule 1, L-FABP, liver fatty acid binding protein, hepcidin-25, cystatin, cystatins, and HAVCR1. Subject headings varied by database and included renal insufficiency, predictive value of tests, diagnosis, sensitivity and specificity, early diagnosis, and biological markers. Full search strategies are available in Item S1 (available as online supplementary material). The search string for each database was tested for rigor by a manual check for key eligible publications and their listed citations. There were no language restrictions. Retrieved citations were downloaded into RefWorks, version 2.0.
Article Eligibility Criteria
Eligibility for full-text review was determined by 2 reviewers (S.W. and K.G.) based on evaluation of the title and abstract of each citation. Any article deemed potentially relevant by either reviewer was retrieved for full-text review. Reference lists of any relevant review articles were also screened to identify studies that may have been missed in the database search. Disagreements were resolved by consensus. Included studies had to be prospective, have a clearly defined AKI outcome (RIFLE [risk, injury, failure, loss, and end-stage renal disease]: "risk [R]" or greater; AKIN [AKI Network]: stage 1 or greater; or KDIGO [Kidney Disease: Improving Global Outcomes]: creatinine criteria), have an observed outcome minimum of 10 AKI events, and report the timing of the biomarker assessment (intraoperative or ,24 hours postoperatively).
Data Extraction
A Microsoft Excel data extraction form was created to capture relevant information from included studies (tables a-b of Item S2). K.G. conducted the extraction with verification by S.W. The following information was extracted for each study: (1) study characteristics, such as year of publication, study design, study population, type of biomarker, and sample size; (2) timing of biomarker measurement; (3) number of documented cases of AKI; (4) details of AKI definition; and (5) estimate of the area under the receiver operating characteristic curve (AUROC) for that biomarker. In cases for which biomarker AUROC was assessed at several time points, the measurement showing the best discrimination within the first 24 hours was abstracted.
Reporting Quality and Risk of Bias
We used the QUADAS (Quality Assessment of Diagnostic Accuracy Studies)-2 tool to assess risk of bias. 20 We developed operational definitions for high, low, and unclear risk of bias for each of the 14 QUADAS-2 domains (Table S1 ). Each study was then reviewed by C.R. and R.B. and rated as high, low, or unclear risk of bias for each of the 14 QUADAS-2 domains. Disagreements between reviewers on any item were settled by consensus between the reviewers. We summarized both individual ( Fig S1) and aggregate ( Fig S2) risk of bias data for the included studies.
Statistical Analysis
AUROCs with 95% confidence intervals (CIs) for each biomarker were extracted and tabulated for each time period reported (intraoperative and postoperative). These data were used to generate forest plots for each biomarker within each time period of interest. A random-effects estimate of the composite AUROC with 95% CI was calculated using the Hartung-Knapp-Sidik-Jonkman method for each biomarker having a minimum of 3 data points. 21 Individual study AUROCs were weighted inversely to the size of their standard errors. Study heterogeneity was assessed using I 2 and the Cochrane Q test; because both were concordant, we report the I 2 . In separate sensitivity analyses and when numbers permitted, we recalculated the biomarker composites after: (1) excluding studies with fewer than 30 AKI events, (2) stratifying for the AKI definition used (AKIN/KDIGO vs RIFLE), (3) stratifying for use of combined urine output and creatinine criteria versus use of creatinine criteria alone, and (4) stratifying for early (#6 hours) versus later (.6 hours) biomarker sampling in the postoperative period. All analyses were conducted by a statistician (B.M.H.).
RESULTS
Search Results and Study Selection
The search retrieved 5,035 unique citations for screening; 265 articles were identified as potentially relevant based on title and abstract and were selected for full-text review. Of these, 28 articles met criteria for inclusion in the study (Fig 1; Table S2 ).
Study Characteristics
Characteristics of the included studies are summarized in Table 1 . All 28 studies were published in English, with 11 originating in North America and the rest representing an international experience from Asia and Europe. Sample sizes were greater than 100 for 13 studies. All were prospective observational studies, with the exception of one that used a randomized controlled trial cohort. 49 The included studies examined a total of 13 urinary (neutrophil gelatinase- and tumor necrosis factor a [TNF-a]) biomarkers. In this article, we use u-, p-, and s-to indicate urinary, plasma, and serum biomarkers, respectively. The studies encompassed a total of 5,122 participants, of whom 956 developed AKI. The number of studies with reportable results for each biomarker is listed in Table 1 . Of these studies, 26 reported diagnostic performance in the early postoperative period, whereas 4 studies reported intraoperative data, defined as the period after induction of anesthesia to closure of the thoracic cavity.
Definition of AKI
Eight studies used the RIFLE; 16, the AKIN; and 3, the KDIGO criteria for AKI. 50 One of the studies used a combined AKIN/RIFLE scheme (Parikh et al 43 ) . Most studies used a minimal threshold for AKI (RIFLE R or AKIN 1), whereas 2 studies set higher thresholds (Liang et al 30 
Risk of Bias
Using the QUADAS-2 tool, we identified several study characteristics that might increase risk of bias (Figs S1 and S2). Domain 1 of the QUADAS addresses patient selection and diagnostic spectrum bias. Although most studies included a general cardiac surgery population with minimal exclusions, several studies did not clearly delineate the selection criteria for the test cohort. Moreover, some studies selected narrower spectrum populations based on risk of AKI (Parikh et al 43 46 ] ). Test performance derived from those studies may not be the same as in less selected populations. Domain 3 addresses aspects of the reference standard. Incomplete or inconsistent operationalization of the chosen reference standard for AKI (RIFLE, AKIN, or KDIGO) was evident in many of the studies. For example, most studies did not apply the urine output subcriteria, although this is a specified component in all AKI classification schemes. Many smaller deviations were also common: for example, many studies using AKIN extended the time frame for creatinine level increase from 48 to 72 hours or applied only the absolute or relative creatinine level increase criteria, but not both.
Finally, in domain 4 (study flow), less than a third of studies provided an accurate accounting of dropouts, and less still provided a STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) or similar diagram for the study.
Intraoperative Biomarker Measurement
A total of 4 studies reported biomarkers in the intraoperative period ( which was insufficient to allow calculation of a meaningful composite measure. One of the NAG studies did not report the 95% CI for the AUROC. Overall, u-NGAL and u-KIM-1 had AUROCs , 0.7, whereas u-NAG and u-cystatin C had AUROCs , 0.75.
Postoperative Biomarker Measurement
Twenty-six studies reported the early postoperative diagnostic performance of urinary and/or plasma/ serum biomarkers (Table 3 ). Of these, calculation of a meaningful composite AUROC was possible for 8 urinary and 2 plasma biomarkers ( Fig 2) . u-NGAL (16 studies), u-KIM-1 (6 studies), and u-L-FABP (6 studies) exhibited composite AUROCs of 0.72. The composite AUROCs for u-cystatin C, u-NAG, u-IL-18, u-a-GST, and u-p-GST were all ,0.7 (range, 0.57-0.69). A composite AUROC was not calculated for u-hepcidin (2 studies; AUROCs, 0.73 and 0.77), u-a 1 -microglobulin (2 studies; AUROCs, 0.61 and 0.62), the product of u-TIMP-2 and u-IGFBP7 concentrations (1 study; AUROC, 0.81), and u-hepatocyte growth factor (1 study; AUROC, 0.67). Two plasma biomarkers were meta-analyzed, and both p-NGAL (6 studies) and p-cystatin C (5 studies) had composite AUROCs , 0.75 (Fig 3) . A single small study reported individual AUROCs for s-uric acid (0.77), s-TNF-a (0.76), and s-MCP-1 (0.66), respectively ( Table 3) .
Heterogeneity Testing and Sensitivity Analyses
Between-study heterogeneity was visually apparent on forest plots and tables for most biomarkers and was statistically significant for u-NGAL (I 2 5 81.1%; P , 0.001), u-KIM-1 (I 2 5 84.0%; P , 0.001), u-IL-18 (I 2 5 59.1%; P 5 0.04), and u-L-FABP (I 2 5 83.8%; P , 0.001).
We performed several sensitivity analyses to see whether we could identify sources of this heterogeneity (Tables 4-6 ). First, we examined whether event rate might influence AUROC estimates by excluding all studies with fewer than 30 AKI events. In general, the composite AUROCs were similar after exclusion of low-event-rate studies. Second, we examined whether inclusion of urine output criteria in the classification of AKI had any bearing on test performance. This was possible only for u-NGAL, for which sufficient numbers of studies with and without urine output criteria were available. A clear difference was noted in measured test performance: the AUROC with urine criteria applied was 0.85 (95% CI, 0.62-1.00) versus 0.69 (95% CI, 0.64-0.75) without, suggesting that this may be an important source of variability in apparent test performance. The choice of definition of AKI may also contribute to variability in the estimates. Again, due to the paucity of data points, it was possible to directly compare definitions only for u-NGAL. Performance of u-NGAL was higher in studies using KDIGO versus AKIN. Moreover, when studies using AKIN were excluded, the performance of p-NGAL and p-cystatin C appeared modestly higher (Table 5 ). Finally, we examined whether timing of the urine or plasma biomarker sample affected test performance estimates. Both u-and p-NGAL appeared to perform better earlier than later (Table 6 ). u-KIM-1 performed slightly worse when a study with late sampling (.6 hours) was excluded. u-IL-18 performance did not change when a study with early sampling (#6 hours) was excluded. Plasma cystatin performance was slightly less when a late sampling study was excluded. u-L-FABP and u-pand u-a-GST performance did not appear affected by exclusion of studies sampling after 6 hours.
DISCUSSION
Our meta-analysis of biomarkers in the early detection of AKI following cardiac surgery has 2 important findings. First, we found that current biomarkers have generally poor and at best moderate discrimination for AKI when measured within the first 24 hours after cardiac surgery in adults. Second, at present, there are comparatively few data for the discrimination of these biomarkers in the intraoperative period, a time of potential active management to mitigate kidney injury. Only u-NGAL has been studied more than once, but its intraoperative diagnostic performance was limited. Our findings highlight the need for further investigation into the early detection of cardiac surgery-associated AKI, particularly given the need for early prevention and treatment of this prescheduled ischemia-reperfusion injury event.
Several other published systematic reviews have examined the performance of selected biomarkers for early diagnosis of AKI in a variety of clinical settings (eg, cardiac surgery, intensive care unit, and after coronary angiography) and age groups (ie, children vs adults). 19,50-55 These reviews have addressed multiple biomarkers, 50 Abbreviations: AKI, acute kidney injury; AUROC, area under the receiver operating characteristic curve; CI, confidence interval; CPB, cardiopulmonary bypass; fHb, free hemoglobin; KIM, kidney injury molecule; NAG, N-acetyl-b-D-glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; NR, not reported. L-FABP, 54 and KIM-1. 56 Our analysis distinguishes itself from prior studies by its focus on a single clinical setting (cardiac surgery), age group (adults only), and outcome (AKI in the postoperative period). In addition, we were able to incorporate new studies of known biomarkers, as well as summarize performance of several newer biomarkers (ie, MCP-1, TNF-a, uric acid, pand a-GST, TIMP-2, and u-IGFBP7).
Our composite AUROC estimates for NGAL, KIM-1, cystatin C, and IL-18 are lower than the pooled estimates reported in other systematic reviews. These differences most likely relate to important differences in the study populations included. First, in most cases, previous meta-analyses included pediatric studies and pooled biomarker test performance across studies in children and adults, whereas we excluded studies in children. Because several biomarkers appear to perform better in children, inclusion of studies of children would have improved the pooled performance estimates in those studies. For example, both NGAL in the review by Haase et al 51 and IL-18 in the review by Liu et al 54 were shown in sensitivity analyses to perform better in studies of children than in studies of adults. It must be noted that this may not be true of all biomarkers because better performance in child populations was not seen for KIM-1. 55 Second, prior reviews also included and pooled studies in a variety of clinical settings, not just cardiac surgery as in our review, which may have further contributed to the differences in pooled estimates. Finally, our analysis included newer studies, some of which observed lower discrimination for a given biomarker. As a result of these differences, our pooled estimates may more closely reflect biomarker performance in adults undergoing cardiac surgery.
As with the other systematic reviews, AKI definition was an important source of heterogeneity in our study. We sought to minimize this heterogeneity by requiring included studies to adhere to a validated AKI classification scheme. Even so, most studies deviated from these criteria. The most frequent deviation was ignoring the urinary criteria altogether. Although a debate on the validity of urinary criteria for AKI is beyond the scope of this study, variable adherence to AKI criteria can lead to significant differences in estimates of test discrimination, as was observed for u-NGAL in our analysis.
It is relevant to contrast the performance of biomarkers with that of clinical AKI risk prediction models. To date, 3 independently validated models have been developed to predict renal replacement therapy after cardiac surgery. 2, 57, 58 Of these, the Thakar score has gained the widest acceptance, having demonstrated good to excellent discrimination in both the original derivation and validation cohorts (AUROCs of 0.81 vs 0.82, respectively) and in later independent validation studies (AUROCs of 0.86 and 0.82, respectively, for AKI requiring dialysis). 59, 60 These AUROCS are significantly higher than those estimated for urine and blood biomarkers in our metaanalysis. However, it is important to clarify that clinical AKI models were derived to predict severe AKI requiring dialysis and so are not directly comparable to the studies included in our systematic review, which examined less severe forms of AKI. Only 2 studies examined the discrimination of biomarkers for moderate to severe AKI, 30, 43 so it was not a-GST possible to determine whether newer biomarkers might better predict severe AKI. Moreover, even in the large Translational Research Investigating Biomarker Endpoints in AKI (TRIBE-AKI) study, 43 only 15 patients needed dialysis. Thus, the lack of studies large enough to address this question (ie, can biomarkers accurately diagnose severe AKI) reflects an important knowledge gap.
There are a number of clinical and research implications to our findings. Despite the growing availability of rapid point-of-care tests for many biomarkers, the current evidence does not support their routine clinical use for early prediction of AKI after cardiac surgery in adults. No biomarker studied to date appears to have adequate levels of discrimination for this purpose. From a research perspective, the paucity of biomarker data in the intraoperative and very early postoperative period needs to be addressed because kidney injury is most likely to be reversible shortly after the renal insult. Efforts to identify newer biomarkers or novel ways to use known biomarkers are urgently needed. Moreover, large studies are needed to examine the ability of biomarkers to diagnose severe AKI. Finally, robust clinical prediction models integrating newer biomarkers and clinical variables need to be developed and validated prior to widespread clinical use. In this context, ----
--
Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; AUROC, area under the receiver operating characteristic curve; CI, confidence interval; GST, glutathione S-transferase; IL, interleukin; KDIGO, Kidney Disease: Improving Global Outcomes; KIM, kidney injury molecule; L-FABP, liver-type fatty acid binding protein; NAG, N-acetyl-b-D-glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; RIFLE, risk, injury, failure, loss, end-stage renal disease. 
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because variation in choice and application of reference AKI criteria can lead to differences in estimates of test performance, it is important that future studies use consistent and carefully applied AKI criteria, preferably focusing on the more severe and clinically significant manifestations of AKI.
Our review has several strengths. First, our search strategy included several electronic databases to maximize the chance of capturing all relevant published literature. In addition, we manually searched the bibliographies of included articles to ensure the sensitivity of our search strategy. Our inclusion criteria were focused: only prospective studies with a validated outcome (AKI) definition and clear timing of biomarker assessment in relation to AKI were included. Given the clinical goal of reliable AKI recognition in the early postoperative period to facilitate potential treatment, we focused on test performance of biomarker measurement within 24 hours postoperatively.
Our study also has limitations. Our review addressed only the question of early diagnosis of AKI in the setting of adult cardiac surgery. We cannot comment on biomarker performance for preoperative risk stratification, in prediction of long-term outcomes, or in other clinical AKI settings such as pediatric heart surgery. We included only published literature in this analysis. Although the direction and magnitude of this publication bias is unknown, it is probable that the majority of unpublished studies were negative (ie, showed weaker discrimination for AKI). Our composite AUROCs based on only published studies may therefore represent an optimistic estimate. In studies with serial biomarker measurements, we selected the most favorable time point (ie, the best AUROC), and this may also overestimate test performance. Similar to other systematic reviews, we reported and metaanalyzed only the raw univariate AUROC. This was necessary because studies either did not adjust for clinical AKI risk factors or varied widely in the choice of variables used for adjustment, precluding meaningful combination of adjusted measures of test discrimination. It follows that we cannot conclude from this analysis whether a combination of clinical variables and selected biomarkers together could create a highly discriminatory predictive model or "test" for AKI. Finally, the majority of studies measured AKI with serum creatinine level, which is known to be a flawed gold standard. Misclassification of AKI status based on this flawed gold standard could have diminished the apparent discrimination of the biomarkers studied.
In conclusion, current biomarkers exhibit at best modest discrimination for cardiac surgery-associated AKI in the early postoperative period in adults. Intraoperatively, only NGAL has been studied to any extent, and its performance is poor. Ongoing efforts to develop new tests for early diagnosis of cardiac surgery associated AKI in adults are still needed. Financial Disclosure: The authors declare that they have no other relevant financial interests.
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